SCHEMBL19435781

SCHEMBL19435781

CCCCCC/C=C\NC(C)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.50
PTPN1 P18031 3/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
PPARA Q07869 3/20 0.50
TOP1 P11387 3/20 0.50
CYP1A2 P05177 2/20 0.50
MAPT P10636 2/20 0.50
CYP2C19 P33261 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FABP4 P15090 2/20 0.50
FAAH O00519 2/20 0.50
KMT2A Q03164 2/20 0.50
GMNN O75496 1/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5806119 1.00 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL19435757 1.00 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL5806115 1.00 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL19435756 1.00 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL5802360 0.98 TERT (0.47) TERTPTPN1PPARGPPARDPPARA
SCHEMBL8610254 0.98 TERT (0.47) TERTPTPN1PPARGPPARDPPARA
SCHEMBL11146490 0.92 F7 (0.44) TERTPTPN1PPARGPPARDPPARA
SCHEMBL30583057 0.84 TERT (0.55) TERTPTPN1PPARGPPARDPPARA
SCHEMBL16466441 0.84 TERT (0.55) TERTPTPN1PPARGPPARDPPARA
SCHEMBL16466440 0.84 TERT (0.55) TERTPTPN1PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170291885-A1 METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291885-A1 METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN ENY2, ENO1, IDH1 TERT 435/4885PTPN1 4721/4885PPARG 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.